TNFRSF1A and myeloid sarcoma: Similarly, the preclinical evaluation of other TNFR1 inhibitors or DN-TNF muteins revealed superior outcomes to global TNF-α blockers in terms of less severe side effects or the potential to treat pathologies such as MS or other neurodegenerative conditions where non-selective TNFα inhibition is not recommended [166].